Abemaciclib + Placebo + Abiraterone acetate + Prednisone
Phase 2/3Active 0 watching 0 views this week๐ Rising
65
Development Stage
โ
Pre-clinicalโ
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer
Trial Timeline
Nov 26, 2018 โ Jun 1, 2026
NCT ID
NCT03706365About Abemaciclib + Placebo + Abiraterone acetate + Prednisone
Abemaciclib + Placebo + Abiraterone acetate + Prednisone is a phase 2/3 stage product being developed by Eli Lilly for Prostate Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03706365. Target conditions include Prostate Cancer.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03706365 | Phase 2/3 | Active |
Competing Products
20 competing products in Prostate Cancer